The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | ANCHOR: melflufen in R/R MM
Enrique M. Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, explains the latest findings of the Phase I/II ANCHOR study NCT03481556): melphalan flufenamide (melflufen) plus dexamethasone, and daratumumab or bortezomib treatment in relapsed/refractory multiple myeloma. Melflufen is a first-in-class peptide-drug conjugate that enables alkylating agents to be released directly into tumor cells. Both arms show encouraging clinical activity and good tolerability. The DARA arm contained more patients, with longer follow up, suggesting consistent responses with continued therapy. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
